On January 10, 2022 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported corporate and portfolio updates in connection with its participation in the J.P. Morgan Annual Healthcare Conference (Press release, Ideaya Biosciences, JAN 10, 2022, View Source [SID1234598553]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Yujiro Hata, President and Chief Executive Officer of IDEAYA, will present at the J.P. Morgan 40th Annual Healthcare Conference on Tuesday, January 11, 2022 at 9:45 am ET. The presentation will be followed by an analyst-hosted Q&A session with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan.
Key corporate and portfolio updates, which the company is planning to discuss in its J.P. Morgan presentation, include:
Strong balance sheet of ~$386 million cash, cash equivalents and marketable securities as of September 30, 2021, is anticipated to fund planned operations into 2025
Completed enrollment into dose escalation Cohort 5 of the Phase 1 clinical trial evaluating IDE397, a potential best-in-class MAT2A inhibitor, in patients with MTAP-deletion tumors; Cohort 5 is an estimated clinically active dose based on the preclinical PDx data
Targeting IDE397 protocol amendment to FDA in Q1 2022 to enable monotherapy cohort expansions, and combination initiation in first half of 2022
Targeting delivery of GSK option data package for IDE397 in first half of 2022 to trigger a review period for potential $50 million opt-in decision
Demonstrated preclinical in vivo efficacy of IDE397 plus standard-of-care combination agents, including with paclitaxel in head and neck cancer
Targeting PARG inhibitor IND submission in fourth quarter of 2022, subject to satisfactory completion of ongoing preclinical and IND-enabling studies
Targeting initiation of IND-enabling studies for Pol Theta Helicase program in first half of 2022; potential $20 million aggregate GSK milestone payments for preclinical to early Phase 1
Observed Werner Helicase inhibitor in vivo efficacy with approximately 100% tumor growth inhibition; targeting Werner Helicase development candidate nomination in 2023
Enrolling into Phase 2 clinical trial evaluating darovasertib and crizotinib clinical combination in Metastatic Uveal Melanoma; targeting update of clinical data and regulatory guidance on potential registrational clinical trial in first half 2022
Evaluating potential indication expansion for darovasertib into additional MET-driven tumors, such as hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC)
A live audio webcast of IDEAYA’s J.P. Morgan presentation will be available, as permitted by conference host, at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source A replay of available webcasts will be accessible for 30 days following the live event.